Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

  title={Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma},
  author={Jawaher Ansari and Syed Anwer Hussain and Asif Ahsan Ansari and John Glaholm},
  booktitle={Biologics : targets & therapy},
A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptors and the latest to join the armamentarium of drugs available for the treatment of metastatic RCC. Despite recent advances in the development of molecular targeted agents for metastatic RCC… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
3 Citations
28 References
Similar Papers


Publications referenced by this paper.
Showing 1-10 of 28 references

Pfizer. Axitinib (AG-013736) with or without dose titration (increase) in patients with kidney cancer

  • Visit httpwww.dovepress
  • Bethseda, MD: US National Library of Medicine…
  • 2012
1 Excerpt

Axitinib secondline therapy for metastatic renal cell carcinoma (mRCC): five-year (yr) overall survival (OS) data from a phase II trial

  • RJ Motzer, T de La Motte Rouge, AL Harzstark
  • J Clin Oncol
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…